सभी अध्ययन
सक्रिय लेकिन भर्ती नहींचरण3हस्तक्षेपात्मक

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

This important study, called HAELO, is looking for people with Hereditary Angioedema (HAE) to test a new medicine named NTLA-2002. HAE is a condition that causes swelling attacks. The main goal is to find out if NTLA-2002 can effectively prevent these attacks and if it's safe to use. Some participants will receive the new medicine, while others will get a placebo (a treatment with no active drug) to help doctors understand the true effects of NTLA-2002. This study is ‘double-blind,’ meaning neither you nor your study doctor will know which treatment you are receiving at first. This helps ensure fair results. The study will involve a single infusion of the medicine and then careful monitoring over a long period.

एक नजर में

स्थिति
सक्रिय लेकिन भर्ती नहीं
चरण
चरण3
प्रायोजक
Intellia Therapeutics
नामांकन लक्ष्य
80
प्रारंभ
15 Jan 2025
अनुमानित पूर्णता
01 सितम्बर 2027

यह अध्ययन किस बारे में है?

This study, called HAELO, is designed to understand if a new medicine, NTLA-2002, can effectively help people who have a condition called Hereditary Angioedema (HAE). HAE causes sudden, unpredictable swelling attacks in different parts of the body, which can be very painful and even dangerous. Scientists believe NTLA-2002 might be able to reduce how often and how severe these attacks are.

The study aims to compare NTLA-2002 with a placebo. A placebo is like a dummy treatment that doesn't contain any active medicine. This comparison is important because it helps researchers work out if any changes in your HAE attacks are truly due to the new medicine or if they might happen anyway. About 60 people with HAE will take part in this study across different countries.

After an initial period, if you started on the dummy medicine, you'll have the option to receive the actual study medicine, and vice-versa. Everyone involved will be monitored for quite a long time – over two years in total – to carefully check both the effects of the medicine and how safe it is. This careful and thorough approach helps ensure that any new treatment is well understood before it becomes widely available.

मुख्य निष्कर्ष

  • This study is testing a new medicine (NTLA-2002) for Hereditary Angioedema (HAE).
  • It aims to see if NTLA-2002 can reduce HAE attacks and if it's safe.
  • Participants will receive a single infusion – either the new medicine or a placebo.
  • The study lasts over two years with regular check-ups.
  • It's 'double-blind,' meaning you won't know which treatment you get at first.
  • Only people aged 16 and over with specific types of HAE can join.

कौन पात्र हो सकता है?

To join this study, you need to be at least 16 years old and have a confirmed diagnosis of Hereditary Angioedema (HAE) – specifically Type 1 or Type 2. You’ll also need to be able to show your study doctor that you've been having HAE attacks that meet the study's requirements. It's important that you are able to take your usual emergency medicines if you have an HAE attack during the study, and your doctor must agree it's safe for you to stop your regular long-term preventative HAE medicines for the first few months of the study.

There are a few reasons why you might not be able to join. For example, if you have another type of swelling condition that isn't HAE, or if you've had a known bad reaction to certain fat-based particles (called lipid nanoparticles) that are used in the study medicine. Also, if your doctor believes that taking part in the study might not be safe for you because of another health condition, or if you can't commit to following all the study steps, you wouldn't be able to participate.

All participants must also agree not to join any other studies where you're trying out a new treatment for the whole time you're in this study. If you're 16 or 17, your parent or guardian will need to give their permission for you to join, and you'll also need to agree yourself.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. क्या आपकी उम्र 16 वर्ष या उससे अधिक है?
  2. Do you have Type 1 or Type 2 Hereditary Angioedema?
  3. Are you able to use your emergency HAE medicine if needed?
  4. Can you agree to temporarily stop your regular long-term preventative HAE medicines if your doctor says it's safe?
  5. Are you willing to commit to regular clinic visits and follow study procedures for about 28 months?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you decide to take part in this study, you'll first go through a screening period to make sure it's safe and right for you. If you qualify, you'll be randomly assigned to either receive the new medicine, NTLA-2002, or a placebo (a dummy medicine). You will receive this treatment as a single infusion into a vein (like a drip) in your arm.

For the first 28 weeks after your infusion, you'll be closely monitored. During this time, neither you nor your study doctor will know whether you received the active medicine or the placebo. After these 28 weeks, you'll have the option to receive an infusion of the opposite treatment from what you received initially, still without knowing which one you're getting.

Following this, you'll enter a long-term observation period for another 76 weeks. This means the study will involve regular visits to the clinic for assessments, blood tests, and to discuss any HAE attacks you might have. You'll need to use your regular emergency HAE medicines if you have an attack. In total, from the very beginning to the very end, your participation in the study will last for about 28 months (over two years).

संभावित जोखिम और लाभ

Taking part in any study has potential benefits and risks. You might find that the new medicine helps reduce your HAE attacks, or you might contribute important information to medical science that could help future patients. However, there's also a chance you could receive the placebo and not get the active treatment, or that the medicine might not work for you. There could be side effects from the medicine, or from the infusion itself, which your doctor will explain to you. Your safety and well-being are the most important concerns throughout the study, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

स्थान (29)

  • Medical Research of Arizona
    सत्यापित पोस्टकोड
    स्कॉट्सडेल, संयुक्त राज्य अमेरिका
  • University of California, San Diego (UCSD)
    सत्यापित पोस्टकोड
    सैन डिएगो, संयुक्त राज्य अमेरिका
  • Raffi Tachdjian MD, Inc
    सत्यापित पोस्टकोड
    सांता मोनिका, संयुक्त राज्य अमेरिका
  • Allergy & Asthma Clinical Research
    सत्यापित पोस्टकोड
    वालनट क्रीक, संयुक्त राज्य अमेरिका
  • IMMUNOe International Research Centers
    सत्यापित पोस्टकोड
    Centennial, United States
  • Asthma & Allergy Associates
    सत्यापित पोस्टकोड
    Colorado Springs, United States
  • University of South Florida
    सत्यापित पोस्टकोड
    टाम्पा, संयुक्त राज्य अमेरिका
  • मैसाचुसेट्स जनरल अस्पताल
    सत्यापित पोस्टकोड
    बोस्टन, संयुक्त राज्य अमेरिका
  • Washington University in St. Louis
    सत्यापित पोस्टकोड
    सेंट लुइस, संयुक्त राज्य अमेरिका
  • NYU Langone Health - Long Island
    सत्यापित पोस्टकोड
    Mineola, United States
  • माउंट सिनाई में आइकन स्कूल ऑफ मेडिसिन
    सत्यापित पोस्टकोड
    न्यूयॉर्क, संयुक्त राज्य अमेरिका
  • Bernstein Clinical Research Center, LLC
    सत्यापित पोस्टकोड
    सिनसिनाटी, संयुक्त राज्य अमेरिका

सामान्य प्रश्न

What is Hereditary Angioedema (HAE)?

HAE is a rare genetic condition that causes unpredictable episodes of swelling in different parts of the body, such as hands, feet, face, and airways.

What does 'single IV infusion' mean?

It means the study medicine will be given to you only once, directly into a vein, like a drip you might receive at a hospital.

'प्लेसबो' क्या है?

A placebo is an inactive substance or treatment that looks exactly like the real medicine but does not contain any active drug. It helps researchers compare the true effects of the new medicine.

क्या मुझे पता चलेगा कि मुझे असली दवा मिल रही है या प्लेसीबो?

For the main part of the study, neither you nor your study doctor will know which treatment you are receiving. This is called 'double-blind' and helps keep the study fair.

मैं अध्ययन में कितने समय तक रहूँगा?

If you join, your total time in the study will be about 28 months, which is just over two years.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.